Gennao

Gennao Bio is a private genetic medicine company that develops first-class targeted nucleic acid therapeutics using proprietary Gene Monoclonal Antibody (GMAB) platform technology. GMAB is an adaptive technology that utilizes novel cell-penetrating antibodies to non-covalently bind and deliver therapeutic levels of various nucleic acid payloads for selective cell targeting. This non-viral delivery platform differs from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeated dosing, and employs well-established manufacturing processes. Gennao Bio is advancing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.